Last reviewed · How we verify

NCT04508751

PED NEONAT 20-000599 Fetal Body Composition

Completed Phase 1 Results posted Last updated 30 August 2023
What this trial tests

Phase 1 trial testing 3T "Free-Breathing" Fetal Magnetic Resonance Imaging in IUGR in 23 participants. Completed in 18 May 2022.

Timeline
17 August 2020
Primary endpoint
27 September 2021
18 May 2022

Quick facts

Lead sponsorUniversity of California, Los Angeles
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment23
Start date17 August 2020
Primary completion27 September 2021
Estimated completion18 May 2022
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, Los Angeles

Who can join

18 and older, female only, with IUGR or Gestational Diabetes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Maternal Visceral Adipose Tissue Volume Primary · During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Visceral adipose tissue PDFF values will be directly measured from regions of interest.

GroupValue95% CI
Healthy Pregnancy9759378014 – 121081
Pregnant Mothers With Gestational Diabetes169626137736 – 227035
Pregnant Mothers With Infants Diagnosed With IUGR9678782327 – 184784
Fetal Liver PDFF Primary · During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images. The distribution/extent of hepatic fat will be manually delineated/drawn on the 3D MRI images and PDFF maps. This work will be performed by PI Strobel with validation from PI Wu.

GroupValue95% CI
Healthy Pregnancy3.23.0 – 3.3
Pregnant Mothers With Gestational Diabetes5.24.2 – 5.5
Pregnant Mothers With Infants Diagnosed With IUGR1.91.4 – 3.7
Fetal Subcutaneous Tissue Volume Secondary · During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Subcutaneous adipose tissue PDFF values will be directly measured from regions of interest.

GroupValue95% CI
Healthy Pregnancy241232 – 255
Pregnant Mothers With Gestational Diabetes280261 – 295
Pregnant Mothers With Infants Diagnosed With IUGR220205 – 235
Maternal Subcutaneous Tissue Volume Secondary · During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images. The distribution/extent of subcutaneous fat will be manually delineated/drawn on the 3D MRI images and PDFF maps and used to calculate volume of subcutaneous adipose tissue. This work will be performed by PI Strobel with validation from PI Wu.

GroupValue95% CI
Healthy Pregnancy157319126300 – 200028
Pregnant Mothers With Gestational Diabetes216264161461 – 325975
Pregnant Mothers With Infants Diagnosed With IUGR15919784024 – 339707
Maternal Hepatic Fat PDFF Secondary · During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Hepatic adipose tissue PDFF values will be directly measured from regions of interest.

GroupValue95% CI
Healthy Pregnancy2.11.8 – 2.8
Pregnant Mothers With Gestational Diabetes3.22.1 – 3.8
Pregnant Mothers With Infants Diagnosed With IUGR2.21.1 – 5.0

Sponsor's own description

Obesity is an ongoing public health problem that is difficult to treat. There is evidence that obesity has fetal origins. Body composition, including visceral, subcutaneous, brown, and hepatic fat have been found to be important predictors in obesity and metabolic syndrome. Magnetic resonance imaging (MRI) can quantify body composition that does not require radiation but is motion limited. The investigators have developed a motion-compensated MRI sequence, also known as "free breathing" MRI. In this study, the investigators plan to obtain free-breathing MRIs of pregnant women in the third trimester of pregnancy. MRIs will be obtained from healthy mothers, mothers with growth-restricted fetuses, and mothers with gestational diabetes. The different types of adipose tissue will be measured and compared between groups and correlated to birth growth parameters. The goal is this study is to assess if motion-compensated MRI can help predict early growth patterns in infancy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of California, Los Angeles trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04508751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing